Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.945 +0.175 (+6.32%)
Streaming Delayed Price Updated: 10:54 AM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,035,538
Open 2.760
Bid (Size) 2.940 (20)
Ask (Size) 2.950 (23)
Prev. Close 2.770
Today's Range 2.710 - 3.019
52wk Range 4.550 - 26.98
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
From Pomerantz LLP
Via GlobeNewswire
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga

Performance

YTD
-76.8%
-76.8%
1 Month
-58.9%
-58.9%
3 Month
-70.7%
-70.7%
6 Month
-79.1%
-79.1%
1 Year
-85.9%
-85.9%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
From Pomerantz LLP
Via GlobeNewswire
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
Via Benzinga
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Via Benzinga
Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today
Via Stocktwits
Topics ETFs Stocks
Exposures Product Safety US Equities
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Via Benzinga
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery
Via Stocktwits
Topics Death
Exposures Death Product Safety
Here are the top movers in Tuesday's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Via Benzinga
Topics Stocks
Exposures US Equities
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
Via Benzinga
Exposures Product Safety
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
Via Benzinga
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish
Via Stocktwits
Exposures Product Safety
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst
Via Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 2.945
When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 06/03/25 10:54 AM ET
What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 193.89M
How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
Rocket Pharmaceuticals, Inc. - Common Stock has 194M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS